Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more
Neovacs S.A. - Asset Resilience Ratio
Neovacs S.A. (ALNEV) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Neovacs S.A.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Neovacs S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.00 | 0.0% |
| Total Liquid Assets | €10.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Neovacs S.A. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neovacs S.A. Industry Peers by Asset Resilience Ratio
Compare Neovacs S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Neovacs S.A. (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Neovacs S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €8.00 | €22.07 Million | -3.59pp |
| 2023-12-31 | 3.59% | €1.71 Million | €47.53 Million | -10.03pp |
| 2022-12-31 | 13.63% | €6.72 Million | €49.28 Million | -21.06pp |
| 2021-12-31 | 34.68% | €16.84 Million | €48.55 Million | +34.35pp |
| 2020-12-31 | 0.34% | €45.18K | €13.49 Million | +0.30pp |
| 2019-12-31 | 0.03% | €2.48K | €7.54 Million | -- |
| 2018-12-31 | 0.00% | €0.00 | €7.24 Million | -- |
| 2017-12-31 | 51.42% | €6.00 Million | €11.67 Million | +17.07pp |
| 2016-12-31 | 34.34% | €3.21 Million | €9.33 Million | +28.06pp |
| 2015-12-31 | 6.28% | €706.59K | €11.25 Million | +1.30pp |
| 2014-12-31 | 4.98% | €450.56K | €9.05 Million | -5.43pp |
| 2013-12-31 | 10.41% | €798.25K | €7.67 Million | -57.03pp |
| 2012-12-31 | 67.44% | €4.19 Million | €6.21 Million | -12.47pp |
| 2011-12-31 | 79.91% | €10.37 Million | €12.98 Million | +4.33pp |
| 2010-12-31 | 75.58% | €8.07 Million | €10.68 Million | +25.09pp |
| 2009-12-31 | 50.49% | €2.28 Million | €4.52 Million | +38.62pp |
| 2008-12-31 | 11.87% | €1.03 Million | €8.70 Million | -2.42pp |
| 2007-12-31 | 14.29% | €572.45K | €4.01 Million | -- |